Orexo ABORXOF 34 Current Ratio is 2.03 as of Mar. 2026, which is 6% below its 10-year median of 2.17. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 998 Drug Manufacturers companies, Orexo AB ranks better than 51.5% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Orexo AB's current ratio for the quarter that ended in Mar. 2026 was 2.03.
Orexo AB has a current ratio of 2.03. It generally indicates good short-term financial strength.
The historical rank and industry rank for Orexo AB's Current Ratio or its related term are showing as below:
ORXOF'
s Current Ratio Range Over the Past 10 Years
Min: 0.68 Med: 2.17 Max: 3.7
Current: 2.03
During the past 13 years, Orexo AB's highest Current Ratio was 3.70. The lowest was 0.68. And the median was 2.17.
ORXOF's Current Ratio is ranked better than 51.5% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs ORXOF: 2.03
Orexo AB (OTCPK:ORXOF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Orexo AB Current Ratio Related Terms
Orexo AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Orexo AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Orexo AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (ORXOF) has a Current Ratio of 2.03 as of Mar. 2026. This is near median its historical median of 2.17. Over the past decade, Orexo AB's Current Ratio has ranged from 0.68 to 3.70. According to the industry distribution chart, Orexo AB ranks #484 out of 998 companies in the Drug Manufacturers industry, placing it in the top 48.5%.
Is Orexo AB's Current Ratio too high?
Orexo AB's current Current Ratio of 2.03 is near median its 10-year median of 2.17. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 3.70. The Drug Manufacturers industry median Current Ratio is 2.00. Orexo AB's value of 2.03 is 1.5% above this industry median. Based on the distribution chart, Orexo AB ranks #484 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #484 out of 998 companies for Current Ratio. This puts Orexo AB in the upper half of its industry. The industry median Current Ratio is 2.00. Orexo AB's value of 2.03 is 1.5% above this benchmark. Historically, Orexo AB's own Current Ratio has ranged from 0.68 to 3.70 over the past decade. While the company's 10-year median is 2.17 vs. the industry median of 2.00, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Current Ratio of 2.03 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Current Ratio is 2.03, which is near median its own 10-year median of 2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Current Ratio is 2.03, which is near median its 10-year median of 2.17 and 1.5% above the Drug Manufacturers industry median of 2.00. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Current Ratio is 2.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
Current Ratio: 2.03 (near median its 10-year median of 2.17)
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
Industry Position: 1.5% above the Drug Manufacturers median (#484 of 998)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
